Associated Papers
Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis.
Disel U et al.
The Oncologist, 2024
37589222 (PubMed )
Supplement: oyad230_suppl_supplementary_tables.xlsx › Supplementary_Table_2
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX et al.
Molecular Cancer Therapeutics, 2019
31439712 (PubMed )
Supplement: 15357163mct190170-sup-217436_2_supp_5691166_pvrtk4.xlsx › PTPN11_shRNA_data
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Melloni GE et al.
Bmc Bioinformatics, 2016
26860319 (PubMed )
Supplement: 12859_2016_935_MOESM2_ESM.xlsx › Table_S5
Select a paper to view details